Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
FI Mulder, FTM Bosch, AM Young… - Blood, The Journal …, 2020 - ashpublications.org
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …
Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review
S Ballestri, E Romagnoli, D Arioli, V Coluccio… - Advances in …, 2023 - Springer
Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …
with a significant healthcare burden, and represent the main indications for anticoagulation …
Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation
Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently
prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial …
prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial …
Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population …
Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …
Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: A nationwide propensity score–weighted study
Background: Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs)
and warfarin have been extensively compared. However, population-based studies …
and warfarin have been extensively compared. However, population-based studies …
Reversal agents for current and forthcoming direct oral anticoagulants
Over the past 20 years, there has been a shift from vitamin K antagonists to direct oral
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …
Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study
Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …
Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: a retrospective cohort study
Background: Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits
apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk …
apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk …
Comparative effectiveness and safety of non–vitamin K antagonist oral anticoagulants in atrial fibrillation patients
Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …
Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation
MA Mamas, S Batson, KG Pollock, S Grundy… - The American Journal of …, 2022 - Elsevier
To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …